Beijing Airdoc Technology Co., Ltd.

北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2251)

PROFIT WARNING

This announcement is made by the board (the "**Board**") of directors of Beijing Airdoc Technology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on its preliminary assessment of the unaudited consolidated management accounts for the Group for the six months ended 30 June 2026 (the "**2026 Interim Period**") and information currently available to the management of the Group, the Board wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that the Group expects to record a net loss of no more than RMB50.0 million for the 2026 Interim Period as compared to the net profit of the Group of approximately RMB0.44 million for the corresponding period in 2025. Such change was mainly attributable to the following factors: (i) increased investment in research and development (the "**R&D**") and clinical trials: greater investment in the R&D, computing power and medical data governance for the "WanYu" medical large language model and AI Agents across various product lines, to advance multi-centre clinical trials, medical device registration and compliant commercialisation, resulting in an increase in R&D and clinical expenses; (ii) the PBM-AI myopia prevention and control business is currently in a phase of expansion and incubation: while there was growth in the number of partner stores, users and model call volumes, with an increased investment in market, medical services, store deployment, operations and C-end eye health marketing and operations, the revenue contribution and economies of scale from such product line have yet to materialise; and (iii) changes in exchange rates have also had certain impacts on the financial position of the Group. Therefore, the Group has adjusted its organisational structure and leveraged the "WanYu" large language model to empower its middle & back-office functions so as to reduce costs and improve efficiency, thereby partially offsetting the above impacts.

The information contained in this announcement is unaudited and only based on a preliminary assessment by the Board with reference to the information currently available to the management, which has not been audited or reviewed by the independent auditors of the Company or confirmed by the audit committee of the Company, and thus may be subject to further adjustments and may differ from the figures to be disclosed in the interim results to be published by the Company.

As of the date of this announcement, the Company is still in the process of finalising the unaudited consolidated results for the 2026 Interim Period, which is expected to be published before the end of August 2026 in accordance with the requirements of the Listing Rules.

Shareholders and potential investors are advised not to place any reliance on the information disclosed herein but to exercise due caution when dealing in the securities of the Company.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, 21 August 2026

As of the date of this announcement, the Board comprises Mr. ZHANG Dalei, Ms. WANG Lin, Mr. QIN Yong and Mr. WEI Yubo as executive Directors; and Dr. WU Yangfeng, Dr. HUANG Yanlin and Mr. NG Ho Yin Owen as independent non-executive Directors.